Table 1.
| Table 1a. Effects of VD3 supplementation on pre-malignant and malignant endometrial changes in 28-week-old normal weight and obese Pten+/− and wildtype mice. | |||||
|---|---|---|---|---|---|
| N mice per group |
Normal | Multifocal glandular hyperplasia (MFGH) |
MFGH & atypia [focal/multifocal] |
Endometrial adenocarcinoma |
|
| Genotype | |||||
| WT Control | 11 | 11 (100%) | 0 | 0 | 0 |
| + VD3 | 8 | 8 (100%) | 0 | 0 | 0 |
| High fat | 11 | 11 (100%) | 0 | 0 | 0 |
| + VD3 | 10 | 10 (100%) | 0 | 0 | 0 |
| Pten+/− Control | 12 | 5 (42%) | 0 | 7 (58%) [0/7] | 0 |
| + VD3 | 10 | 3 (30%) | 1 (10%) | 6 (60%) [4/2] | 0 |
| High fat | 9 | 2 (22%) | 0 | 6 (67%) [3/3] | 1 (11%) |
| + VD3 | 8 | 3 (37.5%) | 3 (37.5) | 2 (25%) [0/2] | 0 |
| Table 1b. Expression of vitamin D metabolic enzymes and VDR mRNA in the histopathologically normal endometrium or endometrium containing benign or pre-malignant and malignant changes in 28-week-old Pten+/− mice. Mean and SEM of 3–14 mice per group are shown. | ||||
|---|---|---|---|---|
| Changes in the endometrium |
25-OHase | 1α-OHase | 24-OHase | VDR |
| Normal | 1.59+0.30 | 1.40+0.45 | 0.93+0.23 | 4.33+1.85 |
| Benign lesions | 2.04+0.23 | 1.03+0.46 | 0.31+0.08 | 2.21+0.68 |
| Pre-malignant and malignant lesions |
2.48+0.32 | 1.60+0.36 | 1.39+0.46 | 2.36+0.71 |
Pten+/− mice: Chi2=111.737, df=6, p<0.001